RECURSION PHARMACEUTICALS, INC. Deferred Revenue
RECURSION PHARMACEUTICALS, INC. (RXRX) had Deferred Revenue of $1.91 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-08-05
- 2026-06-30: Deferred Revenue, Current $1.91M.
- 2025-12-31: Deferred Revenue, Current $0.00.
| Period end | Deferred Revenue, Current |
|---|---|
| 2026-06-30 | $1.91M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |